Humira adalimumab: Phase III data

In the U.S. double-blind Phase III CLASSIC trial in 299 patients, 30% of patients given the 2 highest doses of Humira had clinical remission at 4 weeks vs. 12% of those given placebo (p=0.004). Remiss...